CHARLOTTESVILLE, Va.--(BUSINESS WIRE)--HemoShear, LLC, a biotechnology research company and leading developer of human and animal cell-based surrogate systems for discovery and assessment of new drug compounds, today announced that it has been awarded up to $4.3 million in a Phase II Small Business Innovation Research (SBIR) grant award from the National Heart, Lung and Blood Institute (NHLBI) of the National Institutes of Health (NIH). The grant will fund work profiling the effects of 50 known drugs upon the human blood vessel system (the vasculature) using HemoShear’s proprietary human vascular surrogate system. The database will be valuable in predicting the safety and efficacy of potential new drug candidates. HemoShear will use proprietary bioinformatics methods to develop a predictive vascular gene signature that can be used to score new drug compounds for vascular safety risk. There are no technologies currently available to the pharmaceutical industry to address this need.
